Pharmaceutical Technology

JULY 11, 2022

The US Food and Drug Administration (FDA) has granted approval for the supplemental Biologics License Application (sBLA) of Horizon Therapeutics for the Krystexxa (pegloticase) injection, given along with methotrexate, to help uncontrolled gout patients attain a complete response to treatment.

Food and Drug Administration 59

Food and Drug Administration FDA Food Safety 59

pharmaphorum

SEPTEMBER 30, 2022

Roche’s Genentech unit bought Jecure Therapeutics and its portfolio of NLRP3 drugs in 2018, focusing on peripheral drugs for NASH, liver fibrosis, gout, inflammatory bowel disease, and cardiovascular diseases, and followed that with the takeover of Inflazome with both peripheral and brain-penetrating candidates in 2020.

Biopharma 59

Biopharma Specialization Sales Leads 59

Pharmaceutical Technology

AUGUST 16, 2022

According to the deal, Horizon will provide the funding to develop the therapy until the conclusion of its two Phase II clinical trials. Recently, Q32 concluded a Phase I clinical trial to evaluate the pharmacokinetics, pharmacodynamics and safety of ADX-914, which showed a pharmacological effect on T cells in healthy subjects.

Food and Drug Administration 52

Food and Drug Administration Pharmacology Food Safety 52

Pharmaceutical Technology

FEBRUARY 18, 2023

According to Globaldata, it is involved in 34 clinical trials, of which 20 were completed, 1 is ongoing, and 13 were terminated. The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Prescription 40

Prescription Engineering Pharmaceutical products Networking 40

MedCity News

MARCH 21, 2023

Sobi said it plans to seek FDA approval of the gout drug, SEL-212, in 2024. If approved, it would compete against Krystexxa, a Horizon Therapeutics drug projected to become a blockbuster seller.

FDA 95

FDA Biopharma Pharma 95

World of DTC Marketing

SEPTEMBER 1, 2021

(PBS.org) Nuplazid, a drug for hallucinations and delusions associated with Parkinson’s disease, failed two clinical trials. In a third trial, under a revised standard for measuring its effect, it showed minimal benefit. Overall, more patients died or had serious side effects on Nuplazid than after receiving no treatment.

FDA 165

FDA Food and Drug Administration Side effects Food 165